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Summary box
 ► In 2017, only 64% of the global estimated incident 
cases of tuberculosis (TB) were reported worldwide, 
the remaining 36% of ‘missing’ cases were either 
undiagnosed, untreated or unreported.
 ► Analysis of the patient cascade of care in India and 
South Africa suggests that these ‘missed’ patients 
are not really missing; most are actively engaging 
the health system (public and private) but not ade-
quately managed.
 ► National TB control programmes need to identify 
gaps and weaknesses along the entire patient care 
cascade, addressing barriers to appropriate diag-
nosis, linkages to treatment postdiagnosis while 
strengthening both public and private healthcare 
sectors, and bridging the gap between provider 
knowledge and practice.
 ► Integration of TB services within universal health 
coverage is critical for identifying and managing 
missing patients with TB.
AbSTrACT
Tuberculosis (TB) remains an enormous public health concern 
globally. India and South Africa rank among the top 10 high 
TB burden countries with the highest absolute burden of TB, 
and the second highest rate of TB incidence, respectively. 
Although the primary drivers of TB transmission vary 
considerably between these two countries, they do indeed 
share common themes. In 2017, only 64% of the global 
estimated incident cases of TB were reported, the remaining 
36% of ‘missing’ cases were either undiagnosed, untreated 
or unreported. These ‘missing TB cases’ have generated 
much hype for the challenges they present in achieving the 
End TB Strategy. Although India and South Africa have indeed 
made significant strides in TB control, analysis of the patient 
cascade of care clearly suggests that these ‘missed’ patients 
are not really missing—most are actively engaging the health 
system—the system, however, is failing to appropriately 
manage them. In short, quality of TB care is suboptimal and 
must urgently be addressed, merely focusing on coverage 
of TB services is no longer sufficient. While the world awaits 
revolutionary vaccines, drugs and diagnostics, programmatic 
data indicate that much can be done to accelerate the 
decline of TB. In this perspective, we compare and contrast 
these two national epidemics, and explore barriers, with a 
particular focus on the role of health systems in finding the 
missing millions.
Tuberculosis (TB) remains an enormous 
public health concern causing disease in an 
estimated 10 million people globally in 2017.1 
In addition, TB is one of the top 10 causes of 
death worldwide, and has been the leading 
cause of death from a single infectious agent 
for the past 5 years, surpassing even that of 
HIV/AIDS.2 Such statistics are disconcerting 
given the reality that TB is not a new disease 
but rather one that has plagued populations 
for millennia, and especially since the majority 
of people who develop TB can be cured with 
a timely diagnosis and appropriate manage-
ment.2 The WHO’s End TB Strategy and the 
United Nations’ Sustainable Development 
Goals share a common aim to end the global 
TB epidemic, targeting an 80% reduction in 
TB incidence by 2030 compared with 2015.2 
At the current global decline in TB incidence 
of just 2% per annum, these targets will almost 
certainly be unattainable.1
India and South Africa rank among the 
top 10 high TB burden countries. With 2.7 
million new cases in 2018, India has the 
highest absolute burden of TB.1 With 567 new 
cases per 100 000 population, South Africa 
has the second highest rate of TB incidence.1 
Despite these top ranks, and collectively 
accounting for 31% of the world’s burden of 
TB, and 37% of TB deaths,1 the nature of the 
epidemic in South Africa and India is consid-
erably different (table 1). In this perspective, 
we compare and contrast these two national 
epidemics, and explore barriers, with a partic-
ular focus on the role of health systems in 
finding the missing millions.
IndIA
India’s TB epidemic is driven by poor social 
conditions, notably poverty, overcrowding, 
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Incidence* 2 740 000 322 000 1
HIV-positive TB incidence* 86 000 193 000 1
Mortality* 421 000 78 000 1
GDP spent on health† (%) 1 8.6 4 44
Missing patients with TB‡ 
(%)
25.7 5 45
General healthcare seeking 
in public sector (%)
20 71.2§ 46
General healthcare seeking 
in private sector (%)
80 27.4¶ 7 46
*2017 data, absolute numbers.
†2015 data.
‡2016 data, represents share by country of the missing 4 million 
patients with TB globally.
§In 2017, 71.2% of households indicated they would first go 
to public clinics, hospitals or other public institutions when 
members fall ill or get injured.
¶In 2017, 27.4% of households indicated they would first 
consult a private doctor, private clinic or hospital when 
members fall ill or get injured.
GDP, gross domestic product; TB, tuberculosis.
Figure 1 The cascade of care for all forms of tuberculosis (TB) in India’s Revised National TB Control Program (RNTCP), 2013. 
Error bars depict 95% CIs (Adapted from Subbaraman et al11).
malnutrition and tobacco smoking.3 HIV is not a major 
driver of the Indian TB epidemic. Government invest-
ments in health are low, at approximately 1% of the 
national gross domestic product.4 Despite the high TB 
burden, India is still reliant on old tools. For example, 
India only recently switched to daily drug regimens, 
having used intermittent regimens for decades. While 
rapid molecular testing is being scaled up, the country 
performs about 10 smears for every Xpert MTB/RIF 
test (which is a much superior rapid molecular test).3 5 
The Indian healthcare system is complex and highly 
heterogeneous, comprising formal and informal, 
private and public sector providers.6 While free TB 
care is available in the public sector via a vertically 
run directly observed treatment, short course (DOTS) 
programme called Revised National TB Control 
Program (RNTCP), an estimated 50% of patients with 
TB are managed outside of RNTCP.7 8 More recent 
data suggest that the proportion of patients with TB 
managed in the private sector might be even higher. TB 
drug sales in the private market suggest that over 2.2 
million patients with TB may be managed in the private 
health sector each year, which is twice the number 
managed in the public sector.9
Several systematic reviews highlight the magnitude and 
reasons for poor diagnostic and treatment outcomes in 
India. An average patient with TB experiences a median 
diagnostic delay of 55 days, after consulting almost three 
healthcare providers.6 Another recent systematic review 
of 47 studies assessed quality of TB care. In 10 of 22 
studies assessing providers’ knowledge, less than half of 
the providers surveyed had correct knowledge on the use 
of sputum smears for TB diagnostic purposes.10 In three 
of four studies evaluating self-reported practices, less than 
25% of providers reported ordering a smear in patients 
with chest symptoms, and in 11 of 14 studies assessing 
treatment, less than one-third exhibited correct knowl-
edge of the standard treatment for drug-susceptible TB.10
A recent analysis of the cascade of TB care in India 
reported that in 2013 (figure 1), 72% of the estimated 
2.7 million cases presented to government TB diagnostic 
services. Only 45% of estimated TB cases completed 
treatment. Of the 55% of cases for which treatment was 
not completed, half did not access diagnostic services.11 
The residual 28% that did not seek care in the public 
sector are thought to account for much of the missing TB 
cases in India. A considerable proportion of these cases 
are treated by private sector providers.11
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Figure 2 The cascade of care for all forms of tuberculosis in South Africa, 2013. Error bars depict 95% CIs (Adapted from 
Naidoo et al18).
India’s private healthcare sector is fragmented, unreg-
ulated and comprises diverse types of providers, from 
allopathic (or Western medicine) doctors to practitioners 
of complementary medicine as well as informal health-
care providers with little or no formal qualifications; 
quality of TB care is subsequently often suboptimal.3 12 
In a systematic review conducted by Satyanarayana et al, 
11 studies reported higher levels of TB knowledge and 
optimal provider practices among providers in the public 
sector, as compared with private sector.10 Das et al further 
confirmed the substandard levels of care in the private 
sector. Using standardised (simulated) patients in large 
studies in multiple cities, they showed that only about a 
third of TB cases are correctly managed in the private 
sector. Their study revealed a substantial know-do gap 
between private providers’ knowledge and practices 
related to TB diagnosis and treatment.12 13
Recent standardised patient studies, covering four 
Indian cities, provide additional insights on how Indian 
private pharmacies manage patients with suspected or 
known TB.14 15 Correct management of the simulated 
patients ranged from 13% to 62%, increasing with the 
certainty of the TB diagnosis. Antibiotics were frequently 
dispensed over the counter to simulated patients, with 
16%–37% receiving such drugs across the cases. On a 
positive note, these studies showed that no pharmacy 
dispensed first-line anti-TB drugs. A common thread 
across all the simulated patient studies of TB in India is 
the low rates of TB testing by a variety of private providers, 
even when patients present with textbook description of 
suspected TB. Instead, empirical, broad-spectrum anti-
biotic and non-specific therapies was the norm. Thus, 
even when patients seek care, they get missed, or have a 
delayed diagnosis.
SouTH AfrICA
South Africa shares many of India’s social problems and 
weaknesses in the healthcare system, but, unlike India, 
its TB epidemic is primarily driven by its convergent HIV 
epidemic. In 2016, South Africa’s HIV prevalence was 
12.7% with an estimated antiretroviral therapy (ART) 
coverage of 56%.16 South Africa had the highest number 
of HIV-associated TB cases worldwide in 2017, with 59.9% 
of incident TB cases coinfected with HIV.1 HIV-positive TB 
mortality accounted for 71.8% of deaths among patients 
with TB.1 Traditional cohort analysis reports that 75% 
of patients started on treatment are successfully treated. 
However, Naidoo et al conducted a detailed cascade of 
care analysis on 2013 programmatic data and found that 
just 53% of the estimated TB cases resulted in successful 
treatment completion (figure 2).17 18 Their study revealed 
the following stepwise losses along the pathway in the 
public sector, from care seeking to treatment completion: 
5% were not able to access TB tests, 13% did not receive 
a TB diagnosis, 12% were not initiated on treatment and 
17% failed to successfully complete treatment.18
The small percentage of cases unable to access diag-
nostic services in South Africa is a reflection of the 
extensive network of free primary healthcare facilities 
(mostly run by nurses) in the country.18 However, the 
losses reported along the patient cascade of care are a 
reflection of weak health systems. In fact, the findings 
of numerous studies have alluded to diagnostic delay 
or poor implementation of guidelines, reinforcing the 
importance of health systems strengthening within the 
realm of TB control. In 2015, five years after the incor-
poration of the recommendation that TB-HIV coinfected 
patients initiate ART irrespective of CD4 count, 15.5% 
of patients with TB-HIV did not initiate ART,19 only 38% 
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of newly enrolled HIV-positive patients received isoniazid 
preventive therapy (IPT) in 2015.20 In 2013, the median 
time to treatment initiation among new rifampicin-resis-
tant patients with TB was 22 days, despite the introduc-
tion of Xpert MTB/RIF in November 2010, an assay that 
accurately detects rifampicin resistance in just 2 hours.21 
Indeed, Qin et al reported that less than 60% of individ-
uals with presumptive TB were tested with Xpert MTB/
RIF while the remainder received less reliable smear 
microscopy.22 Such deviations from diagnostic algo-
rithms may partially account for the 13% of TB cases lost 
between TB testing and diagnosis in the patient cascade 
of care.18
Furthermore, general management of patients 
presenting with classic TB symptoms appears to be weak. 
Kweza et al estimated that primary healthcare clinics, 
which are mostly run by qualified nurses, miss 62.9%–
78.5% of patients with TB seeking healthcare for TB-re-
lated symptoms.23 Similarly, Claassens et al reported that 
only 8% of individuals presenting for TB-related symp-
toms were screened for TB and only 3% of individuals 
presenting with TB-related symptoms but seeking health-
care for alternative reasons were screened at two primary 
healthcare facilities in Cape Town.24 Chihota et al found 
that only 22% of individuals with TB-related symptoms 
were requested to provide a sputum sample for TB 
testing.25
A recent simulated patient study from South African 
primary health clinics in two provinces showed that 
only 43% of interactions resulted in simulated patients 
receiving a TB sputum test and being offered an HIV 
test. TB sputum tests were conducted routinely (84%) 
while HIV tests were offered less frequently (47%).26 The 
11 country-patient pathways analysis shows that nearly 
one-third of South Africans seek initial care outside the 
public system. Private providers are less likely to order a 
sputum test and patients accessing private care experi-
ence longer diagnostic delays.6 27–31 The findings of these 
studies reveal the magnitude of missed opportunities in 
the patient cascade of care that may be fuelling disease 
transmission.
Common THemeS from IndIA And SouTH AfrICA
The cascade of care analysis in both India and South 
Africa shows that a quarter of cases that reached govern-
ment diagnostic centres were not diagnosed, or success-
fully diagnosed and lost to follow-up prior to TB treat-
ment initiation.11 18 Using a transmission model, a recent 
study in South Africa found that active case finding and 
loss to pretreatment follow-up were the two most effective 
interventions with the potential to effect a considerable 
impact on the TB burden. However, given the current 
structure of the healthcare system, reducing pretreat-
ment loss to follow-up was predicted to be more easily 
achievable than active case finding,32 due to funding and 
human resource constraints.33 Furthermore, data from a 
recent study have indicated that current approaches to 
active case finding have yielded limited impact, failing 
to produce the expected results. In fact, the Zambia-
South Africa TB and AIDS Reduction (ZAMSTAR) 
study conducted in Zambia and South Africa found that 
expanded active case finding had no impact on either 
population level or paediatric TB incidence.34
The patient cascade of care however shows that a 
substantial percentage of cases engage with the public 
health sector revealing a major opportunity for health 
systems strengthening. The high burden of disease, 
increasing drug resistance, human resource constraints, 
ageing infrastructure, poor infection control practices, 
slow HIV/TB integration, inadequate training of health-
care workers, centralised services, poor management of 
the healthcare system at all levels, inadequate under-
standing of patient needs and a lack of empowerment 
of patients are just some of the myriad of barriers facing 
National Tuberculosis Programs (NTP) in addressing 
programmatic challenges.18 33 Increasing case detection, 
by upscaling rapid molecular testing particularly in India 
and improving compliance to diagnostic algorithms in 
South Africa, accelerating the time to treatment initia-
tion and enhancing linkage to care are however essen-
tial in retaining these patients.11 Engaging the private 
sector to improve quality of TB care is vital to both coun-
tries, but particularly critical for India, where the private 
health sector dominates. To facilitate public–private mix 
interventions, a road map with clear action points has 
been recently published by WHO, Stop TB Partnership, 
and other stakeholders.35
India has made significant strides in TB control by 
rapidly scaling up TB services, prohibiting the use of 
inaccurate serological tests and introducing mandatory 
notification of all TB cases.3 The Indian government has 
recently published an ambitious National Strategic Plan 
(NSP) to end TB by 2025.36 However, achieving the NSP 
goals will require strengthening both public and private 
healthcare sectors, bridging the gap between provider 
knowledge and practice and backing political commit-
ments with tangible funding and investments.37
Similarly, South Africa has published its NSP for TB 
and HIV38 and made colossal investments, managing the 
largest ART and IPT programmes globally, leading the 
rollout of Xpert MTB/RIF, adopting novel and repur-
posed drugs into clinically proven treatment regimens 
while developing ambitious and comprehensive policy 
guidelines for the management of TB. In fact, South 
Africa is the largest user of both Xpert MTB/RIF and 
bedaquiline. However, new tools alone are insufficient. 
Health system issues such as addressing diagnostic delay, 
improving adherence to diagnostic algorithms and 
amplifying TB screening and testing will prove critical to 
enhancing the impact of new tools. Recognising this, the 
South African government recently launched a quality 
improvement (QI) programme to address the major gaps 
identified in the cascade of care analyses.39
Early case detection and appropriate treatment is 
fundamental to TB control, the delay of which allows 
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for disease progression, increases the risk of morbidity 
and mortality and perpetuates community-driven trans-
mission. Importantly, in 2017, only 64% of the estimated 
incident cases of TB were reported, the remaining 36% 
of ‘missing’ cases were either undiagnosed, untreated 
or unreported.1 The ‘missing TB cases’ have generated 
much hype for the challenges they present in achieving 
the End TB Strategy. But evidence from India and 
South Africa clearly suggests that these ‘missed’ patients 
are not really missing—most are actively engaging the 
health system (predominantly private health system in 
India, and predominantly public health system in South 
Africa).40 The system, however, is failing to appropriately 
manage them. In short, quality of TB care is suboptimal 
and must urgently be addressed.41 Merely focusing on 
coverage of TB services is no longer sufficient, as empha-
sised by the recent Lancet Global Health Commission on 
High Quality Health Systems.42
Forty years after Alma-Ata, nearly half the world’s popu-
lation lacks access to essential health services. To address 
this crisis, countries must commit to universal health 
coverage (UHC).43 A strong primary healthcare system is 
the backbone of UHC. However, as reviewed earlier, TB 
is often missed by primary care providers in both public 
and private sectors. So, a big challenge for the TB field 
is the need to rethink the traditional vertical TB care 
delivery model, and integrate TB care within UHC. While 
the vertical approach has been helpful in ensuring donor 
funding and technical expertise, the model’s limitation 
has been exposed by the fact that nearly 40% of patients 
with TB are missing in the DOTS system.
ConCluSIon
TB control programme monitoring must go beyond the 
traditional measures of success such as effective treat-
ment. NTPs need to identify gaps and weaknesses along 
the entire patient care cascade and using the science 
of QI to address barriers to appropriate diagnosis and 
linkages to treatment postdiagnosis.17 Indeed, ending 
the TB epidemic will require rapid scientific advances: 
innovative diagnostic tools, new drugs and an effective 
TB vaccine. However, while the world awaits these revo-
lutionary developments, programmatic data indicate 
that much can be done to accelerate the decline of TB 
by strengthening health systems and improving quality of 
care.
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